Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2026 | $37.00 | Buy | Needham |
| 4/7/2026 | Buy | TD Cowen | |
| 3/19/2026 | $35.00 | Buy | Canaccord Genuity |
| 11/21/2025 | $34.00 | Overweight | Morgan Stanley |
| 11/21/2025 | $28.00 | Buy | Stifel |
| 11/21/2025 | $32.00 | Buy | Jefferies |
| 11/21/2025 | $30.00 | Outperform | Leerink Partners |
S-8 - MapLight Therapeutics, Inc. (0001770069) (Filer)
10-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026Received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to f
SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & P
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (NASDAQ:MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. "The accelerated enrollmen
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
Needham initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $37.00
TD Cowen initiated coverage of MapLight Therapeutics with a rating of Buy
Canaccord Genuity initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $35.00